Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5279627
Max Phase: Preclinical
Molecular Formula: C27H24BrN3O3
Molecular Weight: 518.41
Associated Items:
ID: ALA5279627
Max Phase: Preclinical
Molecular Formula: C27H24BrN3O3
Molecular Weight: 518.41
Associated Items:
Canonical SMILES: COc1cccc(Cc2c(-c3ccccc3)c(C)nn(CC(=O)Nc3ccc(Br)cc3)c2=O)c1
Standard InChI: InChI=1S/C27H24BrN3O3/c1-18-26(20-8-4-3-5-9-20)24(16-19-7-6-10-23(15-19)34-2)27(33)31(30-18)17-25(32)29-22-13-11-21(28)12-14-22/h3-15H,16-17H2,1-2H3,(H,29,32)
Standard InChI Key: OYJTYRBFYHVJQJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 518.41 | Molecular Weight (Monoisotopic): 517.1001 | AlogP: 5.22 | #Rotatable Bonds: 7 |
Polar Surface Area: 73.22 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.69 | CX Basic pKa: | CX LogP: 5.09 | CX LogD: 5.09 |
Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.36 | Np Likeness Score: -1.35 |
1. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM.. (2021) Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential., 213 [PMID:33486199] [10.1016/j.ejmech.2021.113167] |
Source(1):